The New York City-based Mount Sinai Hospital now uses Cellvizio, an endomicroscopy diagnostic device developed by Mauna Kea Technologies.
The Japanese pharmaceutical company Takeda Pharmaceutical and the Raleigh, N.C.-based contract research organization PRA Health Sciences entered a new partnership.
The Palo Alto, Calif.-based biopharmaceutical company twoXAR and Stanford University School of Medicine’s Asian Liver Center will collaborate to identify liver cancer treatments.
Takeda Pharmaceutical, along with Texas Digestive Disease Consultants and the Vanderbilt University Medical Center, are partnering to pilot a digital technology program to help manage inflammatory bowel disease for patients and providers.
The Tel Aviv, Israel-based biopharmaceutical company Galmed Pharmaceuticals named Liat Hayardeny, PhD, MBA, its new chief scientific officer.
The German medical device company invendo medical GmbH received FDA clearance for its invendoscopy E200 System.
More articles on GI company news:
Mount Sinai Hospital adopts Cellvizio System: 3 notes
Takeda Pharmaceutical, PRA Health Sciences enter clinical, operational partnership: 3 notes
Stanford University, twoXAR collaborate on liver cancer treatment: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.